Molbio H1 FY27 profit fell 27% as depreciation and finance costs rose
Key highlights
- Molbio reported H1 FY27 PAT of Rs 60.4 crore, down from Rs 82.9 crore in H1 FY26.
- H1 FY27 EBITDA was Rs 153.4 crore versus Rs 153.2 crore a year earlier, with margin at 22.7%.
- Depreciation increased to Rs 40.4 crore and finance costs rose to Rs 19.6 crore in H1 FY27.
- Truenat test-kit sales held at 9.5 million units, while device sales declined to 559 from 860.
powered by IRIS

In the first half of fiscal year 2027 (H1 FY27), Molbio Diagnostics Limited reported net profit of Rs 60.4 crore, down 27% from Rs 82.9 crore in H1 FY26, as depreciation and finance costs rose. Earnings before interest, tax, depreciation and amortisation (EBITDA) remained nearly unchanged at Rs 153.4 crore.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
Why did Molbio's H1 FY27 profit decline?
Molbio's profit after tax (PAT) declined by Rs 22.5 crore year on year to Rs 60.4 crore, while its PAT margin fell to 8.9% from 12.2%. Profit before tax (PBT) decreased by Rs 24.7 crore to Rs 93.4 crore, indicating that the reduction occurred below the EBITDA line.
The main disclosed changes below EBITDA were a Rs 14.3 crore increase in depreciation and a Rs 9.0 crore increase in finance costs. Depreciation rose from Rs 26.1 crore in H1 FY26 to Rs 40.4 crore in H1 FY27, while finance costs increased from Rs 10.6 crore to Rs 19.6 crore. Tax expense was slightly lower at Rs 33.0 crore against Rs 33.6 crore, but that Rs 0.6 crore reduction did not offset the decline in PBT.
Was Molbio's revenue and operating profit stable in H1 FY27?
Molbio's revenue from operations was Rs 667.4 crore in H1 FY27, compared with Rs 680.0 crore in H1 FY26, a decline of Rs 12.6 crore. Total income, which includes other income, was Rs 676.3 crore, down Rs 5.5 crore from Rs 681.8 crore, because other income rose to Rs 8.9 crore from Rs 1.9 crore.
EBITDA was Rs 153.4 crore in H1 FY27, only Rs 0.2 crore above Rs 153.2 crore a year earlier. EBITDA margin increased to 22.7% from 22.5%, even as employee benefit expenses rose to Rs 83.7 crore from Rs 62.1 crore. Cost of goods sold (COGS) decreased by Rs 8.5 crore to Rs 249.1 crore, and other expenses declined by Rs 17.3 crore to Rs 190.1 crore.
The contrast between EBITDA and PAT is evident in the reported figures. EBITDA stayed near Rs 153 crore across both half-years, but the combined depreciation and finance-cost charge rose to Rs 60.0 crore in H1 FY27 from Rs 36.7 crore in H1 FY26. That Rs 23.3 crore increase was close to the Rs 24.7 crore decline in PBT.
What do Truenat sales show about Molbio's H1 FY27 demand?
Molbio sold 559 Truenat devices in H1 FY27, down from 860 devices in H1 FY26, while Truenat test-kit sales were unchanged at 9.5 million units in both periods. The decline of 301 device units occurred alongside stable test-kit volume, distinguishing instrument sales from consumables sales in the half-year data.
The presentation describes Truenat as a portable, battery-operated molecular diagnostics platform designed for decentralised testing, with relevant workflows delivering results in about 60 minutes. Molbio reported that more than 12,500 Truenat devices had been sold across more than 90 countries, and test kits accounted for about 74% of product revenue in FY26. These figures establish the reported installed-base and consumables context, but the H1 presentation does not provide product-revenue value by devices and kits.
Molbio's assay menu covered 43 assays across 30 diseases as of March 2026. The company also reported 153 research and development professionals and 207 registered patents. Those platform measures provide context for the test-kit portfolio, while the H1 comparison itself shows unit sales holding at 9.5 million despite lower device placements.
Got a follow-up? Ask IRIS
How did Molbio's second quarter compare with the first quarter?
Molbio's Q2 FY27 total income was Rs 264.8 crore, down from Rs 411.5 crore in Q1 FY27 and Rs 581.4 crore in Q2 FY26. Revenue from operations was Rs 259.0 crore in Q2 FY27, compared with Rs 408.4 crore in the immediately preceding quarter and Rs 580.3 crore a year earlier.
Q2 FY27 EBITDA was Rs 49.7 crore, producing an 18.8% margin, versus Rs 103.7 crore and a 25.2% margin in Q1 FY27. Net profit was Rs 7.7 crore, compared with Rs 52.7 crore in Q1 FY27 and Rs 106.8 crore in Q2 FY26. Q2 depreciation was Rs 23.4 crore, higher than Rs 17.1 crore in Q1 FY27, while finance costs fell to Rs 8.9 crore from Rs 10.7 crore sequentially.
Truenat device sales were 395 units in Q2 FY27, above 164 units in Q1 FY27 but below 647 units in Q2 FY26. Test-kit volumes were 3.2 million units in Q2 FY27, down from 6.2 million in Q1 FY27 and 8.7 million in Q2 FY26. Thus, the sequential increase in device units did not coincide with a sequential increase in reported test-kit volume or quarterly income.
What changed in Molbio's balance sheet and cash flow?
Molbio reported total equity of Rs 1,567.3 crore at H1 FY27, compared with Rs 1,308.8 crore at FY26, while total assets rose to Rs 2,328.7 crore from Rs 2,148.4 crore. Cash and cash equivalents on the balance sheet were Rs 493.1 crore at H1 FY27, against Rs 355.5 crore at FY26, and trade receivables declined to Rs 302.3 crore from Rs 408.7 crore.
Non-current borrowings decreased to Rs 193.9 crore at H1 FY27 from Rs 212.4 crore at FY26, and current borrowings fell to Rs 157.7 crore from Rs 200.2 crore. In the half-year cash-flow statement, operating activities generated Rs 167.1 crore, compared with cash used of Rs 239.3 crore in H1 FY26. Investing activities used Rs 141.0 crore, compared with Rs 15.4 crore used a year earlier.
The cash-flow statement reported a net increase in cash and cash equivalents of Rs 115.8 crore in H1 FY27, versus a Rs 194.0 crore decrease in H1 FY26. Financing activities generated Rs 89.6 crore in H1 FY27, compared with Rs 60.6 crore in the prior-year half. The presentation reports these cash-flow movements but does not specify the individual transactions behind the increase in financing cash flow.
Conclusion
Molbio's H1 FY27 figures show a narrow change in operating performance and a larger change in bottom-line profit. Revenue from operations declined by Rs 12.6 crore, EBITDA increased by Rs 0.2 crore and EBITDA margin improved by 0.2 percentage points, but PAT fell by Rs 22.5 crore as depreciation and finance costs increased by a combined Rs 23.3 crore.
The next disclosed operating indicators to watch are Truenat device sales and test-kit volumes, after H1 device sales declined to 559 units while kits held at 9.5 million units. Molbio also reported 43 assays covering 30 diseases as of March 2026 and described an expanding menu across infectious diseases, women's health and oncology, but the presentation gives no timing or financial target for those additions.


